%0 Book
%T NAALADL1 as a key modulator of resistance to Tumor Treating Fields therapy in colorectal cancer
%A Su, Zhaoran
%D 2025
%C Germany; Rostock
%C Universität Rostock
%G English
%F 1984314068
%O vorgelegt von Zhaoran Su
%O GutachterInnen: Michael Linnebacher (Klinik und Poliklinik für Allgemein-, Viszeral-, Thorax-, Gefäß- und Transplantationschirurgie, Universitätsmedizin Rostock) ; Hugo Murua Escobar (Institut und Poliklinik für Medizinische Genetik, Universitätsmedizin Rostock) ; Oliver H. Krämer (Department of Toxicology, Johannes Gutenberg University Mainz)
%O Dissertation Universität Rostock 2026
%X Colorectal cancer (CRC) shows heterogeneous responses to Tumor Treating Fields (TTF), a non-invasive therapy disrupting mitosis. In 21 CRC cell lines, TTF induced microtubule disruption, mitotic defects, metabolic stress, DNA damage, and apoptosis. NAALADL1 was upregulated in resistant cells; its knockdown enhanced TTF sensitivity by stabilizing microtubules and inducing G2/M arrest. Virtual screening identified Lumacaftor and Bestatin as synergistic with TTF, highlighting NAALADL1 as a promising target for personalized CRC therapy.<eng>
%L 570
%9 theses
%9 Text
%9 Hochschulschrift
%R 10.18453/rosdok_id00005800
%U https://purl.uni-rostock.de/rosdok/id00005800
%U https://nbn-resolving.org/urn:nbn:de:gbv:28-rosdok_id00005800-2
%U https://d-nb.info/1420686534/34
%U https://doi.org/10.18453/rosdok_id00005800